Pam Mangat Discusses ASCO's Progress on TAPUR Study

The TAPUR clinical trial is rapidly expanding to new sites, but the researchers have not yet collected enough data to analyze and publish the results, according to Pam Mangat, MS, associate director TAPUR study at the American Society of Clinical Oncology.

The TAPUR clinical trial is rapidly expanding to new sites, but the researchers have not yet collected enough data to analyze and publish the results, according to Pam Mangat, MS, associate director TAPUR study at the American Society of Clinical Oncology (ASCO).

Transcript (slightly modified)

Has ASCO been receiving field data from the TAPUR trial? What results has ASCO seen so far?

ASCO first announced that they would be undertaking a clinical trial in June of 2015, and we launched the study, you know, a short 9 months later, with 37 clinical site locations primarily based in Michigan and North Carolina as our launch sites, to ensure that our processes and procedures worked as anticipated. And the good news is we’ve done that, and now we’re starting to grow. So we’re expanding to another 25 sites and we hope to be by 100 sites by the end of next year.

So all of this is to say that we are collecting data right now from a wide variety of clinical sites, but we don’t have the trial results yet published. But we do have an external data monitoring committee that, once we have cohorts full enough to analyze data, they will take a look at these data points and approve whether or not we would be able to release that. But we have a goal of releasing this data and releasing it to the public as soon as we are able to.